A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

ClinicalTrials.gov ID: NCT04995653

Public ClinicalTrials.gov record NCT04995653. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation (HSCT) to Reduce the Risk of Infection and Graft vs. Host Disease (GvHD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease

Study identification

NCT ID: NCT04995653
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Seres Therapeutics, Inc.; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 23, 2021
Primary completion: Jul 22, 2024
Completion: Jul 22, 2024
Last update posted: Sep 30, 2024

2021 – 2024

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Banner Health - MD Anderson Medical Center	Gilbert	Arizona	85234	—
Mayo Clinic - Scottsdale	Scottsdale	Arizona	85259	—
City of Hope	Duarte	California	91010	—
University of California, Los Angeles - Division of Hematology-Oncology	Marina del Rey	California	90292	—
Georgetown (MedStar Health)	Washington D.C.	District of Columbia	21044	—
University of Florida - Division of Hematology & Oncology	Gainesville	Florida	32610	—
Mayo Clinic - Jacksonville	Jacksonville	Florida	32224	—
University of Chicago Medical Center	Chicago	Illinois	60637	—
Harvard Medical School - Massachusetts General Hospital Cancer Center	Boston	Massachusetts	02114	—
Mayo Clinic - Rochester	Rochester	Minnesota	55905	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
University of North Carolina Chapel Hill	Chapel Hill	North Carolina	27514	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04995653, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 30, 2024 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04995653 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →